PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...
New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society ...
A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently and reliably assess ...
A multicenter study led by London Health Sciences Centre Research Institute (LHSCRI), Lawson Research Institute of St. Joseph ...
A multicenter study led by London Health Sciences Centre Research Institute (LHSCRI), Lawson Research Institute of St. Joseph ...
A multi-centre study whose leads include London-based researchers has found a new imaging solution that can more effectively ...
The Co-PSMA trial has successfully met its primary endpoint, demonstrating that 64 Cu-SAR-bisPSMA PET/CT detects significantly more lesions per patient than the SOC, 68 Ga-PSMA-11 PET/CT. This result ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback